New Step by Step Map For P-gb-IN-1
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To judge numerous intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Principal demo targets were to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyo